We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Ad Astra

5 February 2015 By Neil Unmack

The UK pharma group’s 2014 results disappointed. That shows the challenge CEO Pascal Soriot faces reaching the double-digit growth he promised when seeing off Pfizer’s $118 bln bid. AZ’s full valuation, and maybe its independence, are vulnerable if there are more slips.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)